

Fausto Petrelli

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2221865/fausto-petrelli-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

180
papers

5,502
citations

38
h-index

67
g-index

188
ext. papers

6,762
ext. citations

4.1
avg, IF

6.03
L-index

#	Paper	IF	Citations
180	Survival benefit with adjuvant chemotherapy in stage III microsatellite-high/deficient mismatch repair colon cancer: a systematic review and meta-analysis.. <i>Scientific Reports</i> , 2022 , 12, 1055	4.9	0
179	Third Dose of SARS-CoV-2 Vaccine: A Systematic Review of 30 Published Studies.. <i>Journal of Medical Virology</i> , 2022 ,	19.7	5
178	Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection.. <i>Breast Cancer: Targets and Therapy</i> , 2022 , 14, 101-111	3.9	0
177	Comparison of platinum-based regimens in combination with radiotherapy for head and neck cancers: A network meta-analysis.. <i>Oral Oncology</i> , 2022 , 128, 105864	4.4	
176	Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis. <i>Neoplasia</i> , 2022 , 30, 100809	6.4	1
175	Safety and Effectiveness of Immune Checkpoint Inhibitors in Older Patients with Cancer: A Systematic Review of 48 Real-World Studies. <i>Drugs and Aging</i> , 2021 , 38, 1055-1065	4.7	2
174	Is the oncoType DX test useful in elderly breast cancer patients: a subgroup analysis of real-life Italian PONDx study. <i>Breast Cancer Research and Treatment</i> , 2021 , 191, 477	4.4	0
173	Neoadjuvant or adjuvant immunotherapy in bladder cancer: biological opportunity or clinical utility?. <i>Tumori</i> , 2021 , 3008916211061604	1.7	0
172	Antibody-drug conjugates in treating older patients suffering from cancer: what is the real value?. <i>Human Vaccines and Immunotherapeutics</i> , 2021 , 1-4	4.4	
171	Osimertinib-related venous thromboembolism in non small lung cancer.. <i>Thrombosis Research</i> , 2021 , 210, 63-66	8.2	0
170	Curative treatments for colon cancer during the COVID-19 pandemic era. <i>Tumori</i> , 2021 , 3008916211049828		
169	Reply to the letter to the editor Reply to Solinas et al, venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic reviewSby Frere et al. <i>Thrombosis Research</i> , 2021 ,	8.2	1
168	Outcome of patients with advanced upper tract urothelial carcinoma treated with immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 159, 103241	7	5
167	Adjuvant chemotherapy for pT1abN0M0 triple-negative breast cancer: a systematic review and meta-analysis of published studies. <i>European Journal of Cancer</i> , 2021 , 147, 151-153	7.5	0
166	Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study. <i>Oncologist</i> , 2021 , 26, e1854-e1861	5.7	1
165	Human papillomavirus (HPV) types 16 and 18 infection and esophageal squamous cell carcinoma: a systematic review and meta-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 147, 3011-3023	4.9	3
164	Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. <i>Targeted Oncology</i> , 2021 , 16, 553-568	5	1

163	Therapeutic and prognostic role of vitamin D for COVID-19 infection: A systematic review and meta-analysis of 43 observational studies. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2021 , 211, 105883	5.1	32
162	Survival of Colorectal Cancer Patients With Diabetes Mellitus: A Meta-Analysis. <i>Canadian Journal of Diabetes</i> , 2021 , 45, 186-197.e2	2.1	7
161	Steroids use and survival in patients with glioblastoma multiforme: a pooled analysis. <i>Journal of Neurology</i> , 2021 , 268, 440-447	5.5	13
160	Efficacy of immune checkpoint inhibitors in elderly patients aged ≥ 75 years. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 1777-1780	7.4	3
159	Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA phase 3 randomised trial. <i>Annals of Oncology</i> , 2021 , 32, 66-76	10.3	2
158	Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study. <i>Supportive Care in Cancer</i> , 2021 , 29, 3971-3980	3.9	3
157	Effects of hypertension on cancer survival: A meta-analysis. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13493	4.6	4
156	Is there any place for novel agents in treating biliary tract cancer?. <i>Medical Oncology</i> , 2021 , 38, 19	3.7	
155	Rechallenge of immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 165, 103434	7	6
154	Active surveillance for non-muscle invasive bladder cancer: A systematic review and pooled-analysis. <i>Cancer Treatment and Research Communications</i> , 2021 , 27, 100369	2	2
153	Red blood cell transfusions and the survival in patients with cancer undergoing curative surgery: a systematic review and meta-analysis. <i>Surgery Today</i> , 2021 , 51, 1535-1557	3	3
152	Impact of electrochemotherapy in metastatic cutaneous melanoma: a contemporary systematic review and meta-analysis. <i>Acta Oncologica</i> , 2021 , 1-12	3.2	1
151	Survival of Patients Treated with Antibiotics and Immunotherapy for Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	11
150	Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2020 , 12,	6.6	73
149	Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a analysis from the adjuvant TOSCA trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835919899850	5.4	1
148	Strategies for Increasing the Effectiveness of Aromatase Inhibitors in Locally Advanced Breast Cancer: An Evidence-Based Review on Current Options. <i>Cancer Management and Research</i> , 2020 , 12, 675-686	3.6	14
147	Immunotherapy-based combinations versus standard first-line treatment for metastatic clear cell renal cell carcinoma: a systematic review and meta-analysis. <i>Clinical and Translational Oncology</i> , 2020 , 22, 1657-1663	3.6	3
146	A systematic review of salvage therapies in refractory metastatic colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2020 , 35, 783-794	3	5

145	Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>Journal of Immunotherapy</i> , 2020 , 43, 1-7	5	36
144	Role of lanreotide in an elderly patient with Merkel cell carcinoma. <i>Dermatologic Therapy</i> , 2020 , 33, e13206		1
143	Venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review. <i>Thrombosis Research</i> , 2020 , 196, 444-453	8.2	19
142	Association of steroid use with survival in solid tumours. <i>European Journal of Cancer</i> , 2020 , 141, 105-114	7.5	4
141	A Review of Clinical Practice Guidelines and Treatment Recommendations for Cancer Care in the COVID-19 Pandemic. <i>Cancers</i> , 2020 , 12,	6.6	11
140	Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma. <i>Clinical and Translational Oncology</i> , 2020 , 22, 900-907	3.6	7
139	Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials. <i>Breast Cancer Research and Treatment</i> , 2019 , 174, 597-604	4.4	34
138	Adjuvant chemotherapy in patients with rectal cancer achieving pathologic complete response after neoadjuvant chemoradiation and surgery. <i>European Journal of Cancer</i> , 2019 , 108, 97-99	7.5	4
137	Outcome of head compared to body and tail pancreatic cancer: a systematic review and meta-analysis of 93 studies. <i>Journal of Gastrointestinal Oncology</i> , 2019 , 10, 259-269	2.8	20
136	Timing of Adjuvant Chemotherapy and Survival in Colorectal, Gastric, and Pancreatic Cancer. A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019 , 11,	6.6	25
135	Adjuvant radiotherapy for Merkel cell carcinoma: A systematic review and meta-analysis. <i>Radiotherapy and Oncology</i> , 2019 , 134, 211-219	5.3	24
134	Risk of second primary tumors in GIST survivors: A systematic review and meta-analysis. <i>Surgical Oncology</i> , 2019 , 29, 64-70	2.5	5
133	Use of Antibiotics and Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies. <i>Cancers</i> , 2019 , 11,	6.6	36
132	Surgery or Locoregional Approaches for Hepatic Oligometastatic Pancreatic Cancer: Myth, Hope, or Reality?. <i>Cancers</i> , 2019 , 11,	6.6	16
131	Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2019 , 5, 1268-1275	13.4	37
130	Combination of radiotherapy and immunotherapy for brain metastases: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 144, 102830	7	21
129	Microsatellite Instability and Survival in Stage II Colorectal Cancer: A Systematic Review and Meta-analysis. <i>Anticancer Research</i> , 2019 , 39, 6431-6441	2.3	30
128	Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis. <i>Melanoma Research</i> , 2019 , 29, 1-12	3.3	33

127	One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2019 , 173, 247-254	4.4	23
126	Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis. <i>Gastric Cancer</i> , 2019 , 22, 245-254	7.6	22
125	Biliary tract cancer: current challenges and future prospects. <i>Cancer Management and Research</i> , 2019 , 11, 379-388	3.6	27
124	Association of CDX2 Expression With Survival in Early Colorectal Cancer: A Systematic Review and Meta-analysis. <i>Clinical Colorectal Cancer</i> , 2018 , 17, 97-103	3.8	20
123	Different Toxicity of Cetuximab and Panitumumab in Metastatic Colorectal Cancer Treatment: A Systematic Review and Meta-Analysis. <i>Oncology</i> , 2018 , 94, 191-199	3.6	23
122	Clinical and Molecular Predictors of PD-L1 Expression in Non-Small-Cell Lung Cancer: Systematic Review and Meta-analysis. <i>Clinical Lung Cancer</i> , 2018 , 19, 315-322	4.9	25
121	Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies. <i>PLoS ONE</i> , 2018 , 13, e0201425	3.7	27
120	Stereotactic body radiotherapy for colorectal cancer liver metastases: A systematic review. <i>Radiotherapy and Oncology</i> , 2018 , 129, 427-434	5.3	59
119	A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma. <i>Respiratory Medicine</i> , 2018 , 141, 72-80	4.6	13
118	Addition of radiotherapy to the primary tumour in oligometastatic NSCLC: A systematic review and meta-analysis. <i>Lung Cancer</i> , 2018 , 126, 194-200	5.9	19
117	Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2018 , 103, 7-16	7.5	32
116	Right Versus Left Colon Cancer: Resectable and Metastatic Disease. <i>Current Treatment Options in Oncology</i> , 2018 , 19, 31	5.4	16
115	Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers. <i>European Journal of Cancer</i> , 2017 , 76, 8-16	7.5	19
114	Radical treatment of oligometastatic non-small cell lung cancer: Ready for prime time?. <i>European Journal of Cancer</i> , 2017 , 79, 149-151	7.5	8
113	Clinical outcome and molecular characterization of brain metastases from esophageal and gastric cancer: a systematic review. <i>Medical Oncology</i> , 2017 , 34, 62	3.7	11
112	Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: A meta-analysis of 17 published studies. <i>European Journal of Surgical Oncology</i> , 2017 , 43, 1607-1616	3.6	61
111	Prognostic Role of Primary Tumor Location in Non-Metastatic Gastric Cancer: A Systematic Review and Meta-Analysis of 50 Studies. <i>Annals of Surgical Oncology</i> , 2017 , 24, 2655-2668	3.1	37
110	Borderline resectable pancreatic cancer: More than an anatomical concept. <i>Digestive and Liver Disease</i> , 2017 , 49, 223-226	3.3	10

109	Clinical development of mTor inhibitors for renal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 1229-1237	5.9	37
108	Salvage Therapy in Advanced Adult Soft Tissue Sarcoma: A Systematic Review and Meta-Analysis of Randomized Trials. <i>Oncologist</i> , 2017 , 22, 1518-1527	5.7	12
107	Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis. <i>Hpb</i> , 2017 , 19, 741-748	3.8	33
106	Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature. <i>Breast Cancer Research and Treatment</i> , 2017 , 166, 339-349	4.4	42
105	Disease-free survival is not a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a systematic review of randomized trials. <i>Hpb</i> , 2017 , 19, 944-950	3.8	4
104	The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis. <i>European Journal of Cancer</i> , 2017 , 84, 141-148	7.5	64
103	Second line with oxaliplatin- or irinotecan-based chemotherapy for gemcitabine-pretreated pancreatic cancer: A systematic review. <i>European Journal of Cancer</i> , 2017 , 81, 174-182	7.5	9
102	Salvage treatment for testicular cancer with standard- or high-dose chemotherapy: a systematic review of 59 studies. <i>Medical Oncology</i> , 2017 , 34, 133	3.7	3
101	Position paper on management of iron deficiency in adult cancer patients. <i>Expert Review of Hematology</i> , 2017 , 10, 685-695	2.8	12
100	Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. <i>Annals of Oncology</i> , 2017 , 28, 555-561	10.3	32
99	Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer: A Systematic Review and Pooled Analysis of 19 Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 97, 313-322	4	87
98	Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis. <i>JAMA Oncology</i> , 2017 , 3, 211-219	13.4	380
97	Prognostic Factors of Overall Survival in Upper Urinary Tract Carcinoma: A Systematic Review and Meta-analysis. <i>Urology</i> , 2017 , 100, 9-15	1.6	20
96	Molecules, Drugs, and First-Line Therapies: A Guide for the Cardiologist 2017 , 91-106		
95	Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial. <i>Annals of Oncology</i> , 2016 , 27, 2074-2081	10.3	33
94	Platinum salts in advanced breast cancer: a systematic review and meta-analysis of randomized clinical trials. <i>Breast Cancer Research and Treatment</i> , 2016 , 160, 425-437	4.4	18
93	Vinorelbine With Capecitabine, an Evergreen Doublet for Advanced Breast Cancer: A Systematic Literature Review and Pooled-Analysis of Phase II-III Studies. <i>Clinical Breast Cancer</i> , 2016 , 16, 327-334	3	10
92	Antibiotic prophylaxis for skin toxicity induced by anti-epidermal growth factor receptor agents: a systematic review and meta-analysis. <i>British Journal of Dermatology</i> , 2016 , 175, 1166-1174	4	34

91	Predictive Factors for Reclassification and Relapse in Prostate Cancer Eligible for Active Surveillance: A Systematic Review and Meta-analysis. <i>Urology</i> , 2016 , 91, 136-42	1.6	12
90	Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 33-43	3.5	1
89	Preventing or treating anti-EGFR related skin rash with antibiotics?. <i>Annals of Translational Medicine</i> , 2016 , 4, 312	3.2	4
88	Prognostic factors after R0 resection of colorectal cancer liver metastases: A systematic review and pooled-analysis. <i>Reviews on Recent Clinical Trials</i> , 2016 , 11, 56-62	1.2	9
87	Impact on survival of timing and duration of adjuvant chemotherapy in radically resected gastric cancer. <i>Tumori</i> , 2016 , 102, e15-9	1.7	10
86	Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer: A Meta-analysis of Published Studies. <i>Annals of Surgery</i> , 2016 , 263, 458-64	7.8	174
85	Neoadjuvant dose-dense chemotherapy for locally advanced breast cancer: a meta-analysis of published studies. <i>Anti-Cancer Drugs</i> , 2016 , 27, 702-8	2.4	14
84	Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: A Systematic Review With a Meta-Analysis. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 465-472	3.3	51
83	Which is the appropriate adjuvant endocrine therapy for premenopausal patients with breast cancer?. <i>Clinical Breast Cancer</i> , 2015 , 15, 169-70	3	
82	Adjuvant chemotherapy for rectal cancer. <i>Lancet Oncology, The</i> , 2015 , 16, e152-3	21.7	2
81	Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: a systematic review and pooled-analysis. <i>European Journal of Cancer</i> , 2015 , 51, 800-7	7.5	40
80	Progression-free survival as surrogate endpoint in advanced pancreatic cancer: meta-analysis of 30 randomized first-line trials. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2015 , 14, 124-31	2.1	15
79	Enzalutamide after docetaxel and abiraterone acetate treatment in prostate cancer: a pooled analysis of 10 case series. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 193-8	3.3	19
78	Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials. <i>Breast Cancer Research and Treatment</i> , 2015 , 151, 251-9	4.4	51
77	Efficacy of oxaliplatin-based chemotherapy + bevacizumab as first-line treatment for advanced colorectal cancer: a systematic review and pooled analysis of published trials. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015 , 38, 227-33	2.7	23
76	Prognostic factors for survival with bevacizumab-based therapy in colorectal cancer patients: a systematic review and pooled analysis of 11,585 patients. <i>Medical Oncology</i> , 2015 , 32, 456	3.7	14
75	BRAF-mutated metastatic colorectal cancer between past and future. <i>British Journal of Cancer</i> , 2015 , 113, 1634-5	8.7	10
74	Tumour Budding and Survival in Stage II Colorectal Cancer: a Systematic Review and Pooled Analysis. <i>Journal of Gastrointestinal Cancer</i> , 2015 , 46, 212-8	1.6	46

73	Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. <i>Breast Cancer Research and Treatment</i> , 2015 , 153, 477-91	4.4	141
72	FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies. <i>Pancreas</i> , 2015 , 44, 515-21	2.6	128
71	Efficacy of fourth-line chemotherapy in advanced non-small-cell lung cancer: a systematic review and pooled analysis of published studies. <i>Anti-Cancer Drugs</i> , 2015 , 26, 807-12	2.4	2
70	Hepatic resection for gastric cancer liver metastases: A systematic review and meta-analysis. <i>Journal of Surgical Oncology</i> , 2015 , 111, 1021-7	2.8	26
69	First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 96, 156-66	7	50
68	Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis. <i>Expert Opinion on Biological Therapy</i> , 2015 , 15, 155-62	5.4	26
67	Surveillance or Adjuvant Treatment With Chemotherapy or Radiotherapy in Stage I Seminoma: A Systematic Review and Meta-Analysis of 13 Studies. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 428-34	3.3	18
66	Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies. <i>Acta Oncologica</i> , 2015 , 54, 961-70	3.2	139
65	Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. <i>European Journal of Cancer</i> , 2015 , 51, 587-94	7.5	329
64	A systematic review and meta-analysis of adjuvant chemotherapy after neoadjuvant treatment and surgery for rectal cancer. <i>International Journal of Colorectal Disease</i> , 2015 , 30, 447-57	3	65
63	The Modified Glasgow Prognostic Score and Survival in Colorectal Cancer: A Pooled Analysis of the Literature. <i>Reviews on Recent Clinical Trials</i> , 2015 , 10, 135-41	1.2	23
62	The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2014 , 144, 223-32	4.4	105
61	Radical prostatectomy or radiotherapy in high-risk prostate cancer: a systematic review and metaanalysis. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 215-24	3.3	66
60	A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. <i>Gynecologic Oncology</i> , 2014 , 133, 117-23	4.9	129
59	Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: a systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2014 , 134, 166-71	4.9	48
58	Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: a systematic review and meta-analysis of published studies. <i>Oral Oncology</i> , 2014 , 50, 1041-8	4.4	88
57	Oxaliplatin-based chemotherapy: a new option in advanced hepatocellular carcinoma. a systematic review and pooled analysis. <i>Clinical Oncology</i> , 2014 , 26, 488-96	2.8	34
56	Predictive value of human papillomavirus in oropharyngeal carcinoma treated with radiotherapy: An updated systematic review and meta-analysis of 30 trials. <i>Head and Neck</i> , 2014 , 36, 750-9	4.2	45

55	FOLFIRI with cetuximab or bevacizumab: FIRE-3. <i>Lancet Oncology, The</i> , 2014 , 15, e581-e582	21.7	2
54	PISCES trial: the end does not always justify the means. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3782-3	2.2	2
53	Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. <i>European Urology</i> , 2014 , 65, 350-7	10.2	144
52	Polychemotherapy or gemcitabine in advanced pancreatic cancer: a meta-analysis. <i>Digestive and Liver Disease</i> , 2014 , 46, 452-9	3.3	15
51	Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials. <i>Medical Oncology</i> , 2014 , 31, 776	3.7	19
50	KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials. <i>Medical Oncology</i> , 2013 , 30, 650	3.7	35
49	Non-cancer-related mortality after cisplatin-based adjuvant chemotherapy for non-small cell lung cancer: a study-level meta-analysis of 16 randomized trials. <i>Medical Oncology</i> , 2013 , 30, 641	3.7	10
48	The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. <i>Targeted Oncology</i> , 2013 , 8, 173-181	5	90
47	Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer. <i>Targeted Oncology</i> , 2013 , 8, 291-4	5	14
46	Surrogate end points and postprogression survival in renal cell carcinoma: an analysis of first-line trials with targeted therapies. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 385-9	3.3	15
45	Response to neoadjuvant chemotherapy in ductal compared to lobular carcinoma of the breast: a meta-analysis of published trials including 1,764 lobular breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013 , 142, 227-35	4.4	35
44	Platinum rechallenge in patients with advanced NSCLC: a pooled analysis. <i>Lung Cancer</i> , 2013 , 81, 337-343	3.9	19
43	Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials. <i>Breast Cancer Research and Treatment</i> , 2013 , 140, 233-40	4.4	34
42	A pooled analysis of 2618 patients treated with trastuzumab beyond progression for advanced breast cancer. <i>Clinical Breast Cancer</i> , 2013 , 13, 81-7	3	29
41	FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials. <i>Clinical Colorectal Cancer</i> , 2013 , 12, 145-51	3.8	45
40	FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials. <i>Medical Oncology</i> , 2013 , 30, 486	3.7	16
39	Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer. <i>Annals of Oncology</i> , 2013 , 24, 186-92	10.3	55
38	Cisplatin or not in advanced gastric cancer: a systematic review and meta-analysis. <i>PLoS ONE</i> , 2013 , 8, e83022	3.7	22

37	Cetuximab/irinotecan-chemotherapy in KRAS wild-type pretreated metastatic colorectal cancer: a pooled analysis and review of literature. <i>Reviews on Recent Clinical Trials</i> , 2013 , 8, 101-9	1.2	8
36	The PARAMOUNT trial in NSCLC: is the amount of benefit clinically meaningful?. <i>Annals of Palliative Medicine</i> , 2013 , 2, 161-3	1.7	
35	Bevacizumab in advanced breast cancer: an opportunity as second-line therapy?. <i>Medical Oncology</i> , 2012 , 29, 1-4	3.7	11
34	Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012 , 138, 179-87	4.9	28
33	Mortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: a meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2012 , 135, 335-46	4.4	28
32	Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. <i>Lung Cancer</i> , 2012 , 78, 8-15	5.9	105
31	Role of HER2-neu as a prognostic factor for survival and relapse in pT1a-bN0M0 breast cancer: a systematic review of the literature with a pooled-analysis. <i>Medical Oncology</i> , 2012 , 29, 2586-93	3.7	27
30	Surgery of primary tumors in stage IV breast cancer: an updated meta-analysis of published studies with meta-regression. <i>Medical Oncology</i> , 2012 , 29, 3282-90	3.7	80
29	Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis. <i>International Journal of Colorectal Disease</i> , 2012 , 27, 997-1004	3	46
28	Anti-EGFR-targeting agents in recurrent or metastatic head and neck carcinoma: a meta-analysis. <i>Head and Neck</i> , 2012 , 34, 1657-64	4.2	7
27	A rare case of metastatic pancreatic hepatoid carcinoma treated with sorafenib. <i>Journal of Gastrointestinal Cancer</i> , 2012 , 43, 97-102	1.6	29
26	Meta-analysis of concomitant compared to sequential adjuvant trastuzumab in breast cancer: the sooner the better. <i>Medical Oncology</i> , 2012 , 29, 503-10	3.7	17
25	5-Fluorouracil or capecitabine in the treatment of advanced colorectal cancer: a pooled-analysis of randomized trials. <i>Medical Oncology</i> , 2012 , 29, 1020-9	3.7	21
24	Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials. <i>Clinical Lung Cancer</i> , 2012 , 13, 107-14	4.9	104
23	Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. <i>Annals of Oncology</i> , 2012 , 23, 1672-9	10.3	88
22	Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies. <i>Expert Opinion on Drug Safety</i> , 2012 , 11 Suppl 1, S9-19	4.1	70
21	The risk for anemia with targeted therapies for solid tumors. <i>Oncologist</i> , 2012 , 17, 715-24	5.7	27
20	Biological agents alone or in combination as second-line therapy in advanced non-small-cell lung cancer: systematic review of randomized studies. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 1299-312	3.5	3

19	Turn on the TORCH before treat your patients: a lesson from a first line study in advanced NSCLC. <i>Translational Lung Cancer Research</i> , 2012 , 1, 224-6	4.4	
18	The emerging issue of ratio of metastatic to resected lymph nodes in gastrointestinal cancers: an overview of literature. <i>European Journal of Surgical Oncology</i> , 2011 , 37, 836-47	3.6	24
17	Tamoxifen added to radiotherapy and surgery for the treatment of ductal carcinoma in situ of the breast: a meta-analysis of 2 randomized trials. <i>Radiotherapy and Oncology</i> , 2011 , 100, 195-9	5.3	25
16	Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer: a pooled analysis of two randomized trials. <i>Anti-Cancer Drugs</i> , 2011 , 22, 128-35	2.4	44
15	Erlotinib as maintenance therapy in patients with advanced non-small cell lung cancer: a pooled analysis of three randomized trials. <i>Anti-Cancer Drugs</i> , 2011 , 22, 1010-9	2.4	16
14	Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis. <i>International Journal of Colorectal Disease</i> , 2011 , 26, 823-33	3	49
13	Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debate. <i>Medical Oncology</i> , 2011 , 28, 401-8	3.7	2
12	A patient presenting nasal septum perforation during bevacizumab-containing chemotherapy for advanced breast cancer. <i>Breast Cancer</i> , 2011 , 18, 226-30	3.4	8
11	Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. <i>Journal of Translational Medicine</i> , 2011 , 9, 179	8.5	75
10	Targeted therapies and other agents as first-line maintenance and beyond: particular benefit in pulmonary adenocarcinoma patients. <i>Current Medicinal Chemistry</i> , 2011 , 18, 1640-50	4.3	1
9	Progression of intramedullary metastasis during perioperative cessation of sunitinib. <i>Nature Reviews Urology</i> , 2010 , 7, 634-7	5.5	6
8	Benefit of adjuvant chemotherapy in elderly ER-negative breast cancer patients: benefits and pitfalls. <i>Expert Review of Anticancer Therapy</i> , 2010 , 10, 185-98	3.5	8
7	What else in gemcitabine-pretreated advanced pancreatic cancer? An update of second line therapies. <i>Reviews on Recent Clinical Trials</i> , 2010 , 5, 43-56	1.2	10
6	Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 1413-32	4	83
5	Oral vinorelbine: its role in advanced breast cancer pre-treated with anthracycline and taxane chemotherapies. <i>Oncology Reviews</i> , 2010 , 4, 61-69	4.3	2
4	Is there a role for maintenance therapy in non-small-cell lung cancer? An emerging issue. <i>Expert Review of Anticancer Therapy</i> , 2009 , 9, 1455-65	3.5	1
3	Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based?. <i>Expert Opinion on Investigational Drugs</i> , 2009 , 18, 1467-77	5.9	12
2	Targeted therapies for the treatment of breast cancer in the post-trastuzumab era. <i>Oncologist</i> , 2008 , 13, 373-81	5.7	25

- 1 Toxicity of targeted therapies in elderly patients. *Expert Review of Anticancer Therapy*, **2008**, 8, 1965-76 3,5 4